NOVARTIS $74.15

down -0.86


17/5/2013 05:17 PM  |  NYSE : NVS  |  Industries : Manufacturing / Pharmaceutical and Medicine Manufacturing
12 Mo. Price Change : 42% - NVS has outperformed the S&P 500 by 17%

Get Trend Analysis Icon Get Trend Analysis

Partner Headlines

  1. Are Individual Investors Finally Wising Up? Looking Ahead For a Change

    YCharts

  2. United Therapeutics' Lung Drug Breathes Again

    Investors Business Daily

  3. Is My Doctor On the Payroll of Some Drug Maker? Now Easier to Find Out

    YCharts

  4. Pay-to-Delay Opponent, FTC Chief Leibowitz, Quits: Respite for Pharma?

    YCharts

  5. Pay-to-Delay Charges Against J&J and Novartis in Europe: U.S. ...

    YCharts

  6. Claman's Davos Notebook: Big Names, Bigger Ideas

    FOXBusiness

  7. Will Vasella's Departure From Novartis Lead to Asset Sales?

    YCharts

  8. Med Stocks Moving: Novartis, Map, Celgene, Abbott

    Investors Business Daily

  9. UPDATE: Novartis Posts Rise In Q4 Profit

    Benzinga

  10. FTC: Pay-to-Delay Pharma Deals Cover $8.3 Billion in Revenue

    YCharts

  11. Three Stocks to Buy for Flu Season

    Benzinga

  12. Alkermes In Buy Area After Breakout In Strong Volume

    Investors Business Daily

  13. Do Pharma Stocks Deserve Takeover Premiums? Read This First

    YCharts

  14. Biogen Stock Falls After ALS Candidate Fails

    Investors Business Daily

  15. Patent Victory Gives AstraZeneca Time to Develop New Drugs: Bad News?

    YCharts

  16. Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)

    Benzinga

  17. Dendreon Announces Sale of New Jersey Plant to Novartis for $43M ...

    Benzinga

  18. With Influence Like This, You'd Expect Pharma Stocks to Do Better

    YCharts

  19. Amgen To Pay $762M To Settle Drug Misbranding Case

    Investors Business Daily

  20. Dodge & Cox Explain Why They Are Overweight in Pharmaceuticals

    GuruFocus

  21. Benzinga's Top Downgrades

    Benzinga

  22. J&J's Dividend, Yielding 3.5%: What You Need to Know About Cash ...

    YCharts

  23. Three More Defensive Stock Picks for 2013 (LLY, PFE, VTR)

    Benzinga

  24. 10 For '13: Top Picks Among Europe ETFs For 2013

    Benzinga

  25. Barron's Recap (12/8/12): Ten Stock Picks for 2013

    Benzinga

  26. How Big Pharma Might Get Its R&D Act Together

    YCharts

  27. Pfizer, Stock Rising on Cost Cuts, Plans More Staff Layoffs

    YCharts

  28. Johnson & Johnson's CEO Will Assume Chairman's Role

    Investors Business Daily

  29. Accenture Life Sciences Study: Worst of Pharma's Patent Cliff is ...

    YCharts

  30. Is Novartis a Good Buy Right Now?

    GuruFocus

  31. If Only People Would Take Their Meds – Pharma Sales Might Double

    YCharts

  32. Generics Maker Teva Pharmaceutical to Make Smaller Acquisitions, ...

    YCharts

  33. One Way, Allegedly, to Battle Generic Versions of Drugs: A ...

    YCharts

  34. Meningitis vaccine gets nod

    Investors Business Daily

  35. The Fiscal Cliff and its Impact to your Portfolio

    GuruFocus

  36. Novartis Begins to Fix Manufacturing Problems

    YCharts

  37. Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)

    Benzinga

  38. Pharma's Off-Label Violations Not Limited to the U.S.: Glaxo's ...

    YCharts

  39. Big Pharma on the Defensive: Sanofi Caves on Oncology-Drug, ...

    YCharts

  40. Mylan To Wall Street: Forget Patent Cliff, We'll Grow

    Investors Business Daily

  41. No-Go on Hepatitis Drug Patent in India: More Developing-Country ...

    YCharts

  42. Watson Pharma Starts New Era As Generic Drug Titan

    Investors Business Daily

  43. Watson Pharmaceuticals Earnings, Sales Beat Estimates

    Investors Business Daily

  44. More Quality Problems at Johnson & Johnson (Odious Details Omitted)

    YCharts

  45. Global Squeeze on Pharma Prices Just Won't Ease Up: Canadians Iffy ...

    YCharts

  46. Ah, Geez, the Aussies, Too? Plush Patent Rights of Big Pharma ...

    YCharts

  47. Ken Fisher's Top Mega-Cap New Purchases in Q3

    GuruFocus

  48. Biogen slides on drug delay

    Investors Business Daily

  49. Biogen Stock Slips After FDA Delays MS Drug Review

    Investors Business Daily

  50. Pharmaceutical Stocks Are All-of-a-Sudden Hot Again: Read About ...

    YCharts

  51. Pharma Industry Agrees to Price Cuts With Irish Government: More ...

    YCharts

  52. Don't Call it Bribery  And Whatever it Was, Abbott Stopped Doing ...

    YCharts

  53. One Reason Novartis is Expected to Overtake Pfizer in Revenue: its ...

    YCharts

  54. Golly, Big Pharma, This Emerging Markets Strategy Isn't Looking So ...

    YCharts

  55. Big Pharma's Push Into Emerging Markets Meets More Resistance: ...

    YCharts

  56. Three Biotech Stocks Analysts Are Keen On (ARIA, MACK, GEVA)

    Benzinga

  57. The 20 Biggest Healthcare Dividend Payer

    GuruFocus

  58. Attention Value Shoppers: Deals in the Euro Aisle

    YCharts

  59. ETF Showdown: Swiss Beats

    Benzinga

  60. A Big Part of the Pharma Pipeline is Struggling: Biotech Startups

    YCharts

  61. Delays for India's Ranbaxy Good News for Novartis and its $5.7 ...

    YCharts

  62. Prestige Brand Sees The Ups And Downs Of Buyout Talk

    Investors Business Daily

  63. Yet Another Problem for U.S. Pharma Companies Seeking Growth in ...

    YCharts

  64. This Drugmaker Can't Seem To Shake Its Manufacturing Problems

    YCharts

  65. FDA approves Novartis Afinitor Disperz for Children with Rare ...

    Benzinga

  66. Sanofi Unit Genzyme Hits Delay With MS Drug Filing

    Investors Business Daily

  67. Novartis, Ever-Greening of Patents and Trouble Ahead in Emerging ...

    YCharts

  68. Novartis, Nationstar Mortgage Holdings Among Stocks Setting ...

    FOXBusiness

  69. Zoetis IPO: A First Look At Pfizer's Animal Spinoff

    Investors Business Daily

  70. A Look at Two Undervalued Small-Cap Health Care Stocks

    GuruFocus

  71. United Therapeutics Gets Lift From Expanded Lineup

    Investors Business Daily

  72. 10 Best Yielding Drug Manufacturing Stocks

    GuruFocus

  73. Questcor's Q2 Earnings Beat Expectations

    Investors Business Daily

  74. United Parcel Service, Eli Lilly & Among Stocks Down on High ...

    FOXBusiness

  75. UPDATE: Novartis Posts Upbeat Q2 Profit

    Benzinga

  76. Idenix Pharmaceuticals Lagging Behind in Breakthrough Hepatitis C ...

    GuruFocus

  77. 3 Billion Dollars Fraud Charges Settlement for Glaxo SmithKline

    GuruFocus

  78. Novartis: Strong Stock

    GuruFocus

  79. Teva Stock Rises After Patent Victory On Key Drug

    Investors Business Daily

  80. Growth Spotlight: Novartis AG

    GuruFocus

  81. 20 Best Yielding Stocks From Europe With Safe Heaven Aspects

    GuruFocus

  82. Novartis AG (NVS) Up 1.5% as European Drug Makers Advance

    At Market Intelligence Center

  83. 5 Healthcare Stocks With The Highest Revenue

    Benzinga

  84. Guru Stocks at 52-Week Lows: NVS, BHP, PBR, SI, DCM

    GuruFocus

  85. Blueberries, Gold Bond, Ovaltine and Obesity: The Makings for a ...

    Benzinga

  86. Guru Stocks at 52-Week Lows: NVS, BHP, SI, DCM, COP

    GuruFocus

  87. Watson Q1 Beats Expectations; Eyes Actavis Closing

    at IBD

  88. Watson Stock Pops After Long-Rumored Buyout Confirmed

    at IBD

  89. Novartis, Centene profit weak

    at IBD

  90. Biotechs Grapple With New Rules On Biosimilar Drugs

    at IBD

  91. Novartis AG (NVS) Off 0.01% After Yesterday's Gain

    At Market Intelligence Center

  92. Eight Drug Majors Sued Over Use Of Co-Pay Coupons

    at IBD

  93. UPDATE: JP Morgan Downgrades Novartis to Neutral

    at Benzinga

  94. Financial Breakfast: Morning News Summary for March 6, 2012

    at Benzinga

  95. Seventeen Consistent Dividend Raisers in the News

    at GuruFocus

  96. Find High-Yield Retirement Income From Other Sources

    at IBD

  97. Ex-Dividend Date Reminder for February 27, 2012

    at GuruFocus

  98. Novartis AG (NVS) Trades Up 0.6%, Sees 6x Average Options Volume

    At Market Intelligence Center

  99. Endo Diversifies Drug Lineup To Offset Generic Threat

    at IBD

  100. Johnson & Johnson (JNJ) - A Reliable Dividend Growth Stock

    at GuruFocus
People viewing NVS also viewed: , , , , , ,
Marketplace
Trading Center